which inhibited the expression of androgen receptor (AR), prostate specific antigen (PSA), and Gli 1, and induced apoptosis (M30); cyclopamine was found to inhibit serum PSA in mice harboring chimeric prostate tumours of C4−2 and NPF. Because co-culture of C4−2 and NPF maintained the expressions of Shh and Gli 1 in prostate cancer epithelium. These results suggest prostate cancer cells stimulated the growth of normal/benign but not cancerous prostate stromal cells through Shh-mediated stromal target genes.
Conclusions: A chimeric C4−2 and NPF model was established to assess the role of Shh signaling in human prostate cancer. Shh induced Gli1 target gene expression in normal/benign but not cancerous prostate stromal or bone stromal cells, which confer increased prostate cancer cell growth. A "vicious cycle" mechanism could result from aberrant Shh-Gli1 signaling between prostate cancer and normal/benign stromal cells.

7042 POSTER

Correspondence between Common Terminology Criteria for Adverse Events v3.0 and four self-report toxicity questionnaires during and after radiotherapy for prostate cancer

Y.L. Basta[1], R. Houben[1], F.C.J.M. van Gils[1]. [1]*MAASTRO, Radiotherapy, Maastricht, The Netherlands*

Background: Accurate measurement of side effects of radiotherapy for prostate cancer is important in the development of a more effective treatment. The Common Terminology Criteria for Adverse Events v3.0 (CTCae v3.0) is a standardized scoring system, used for assessing side effects in patients during or after treatment for cancer. Currently no self-report questionnaires, specifically developed to monitor side effects of radiotherapy, such as cystitis and proctitis, are validated. Therefore the aim of this study was to evaluate the correspondence between the CTC and four self-report questionnaires during radiotherapy for prostate cancer.
Methods: 30 patients completed three or four self-report questionnaires, the International index of Erectile Function (IIEF), International Prostate Symptom Score (IPSS), Radiation-Proctitis questionnaire (RPQ) and the Radiation-Cystitis questionnaire (RCQ). IPSS and IIEF have already been validated in urology. The latter two are in house developed questionnaires, based on EORTC questionnaires. A student and a physician independently assessed a CTC. All separate items of the questionnaires were linked to specific CTC scores. The data were introduced in statistical software program SPSS to find a correlation, between the standardized CTC and the questionnaires specialized for prostate cancer, using the Spearman method (CC). Kappa (κ) and the raw agreement were used to estimate the inter-observer variability.
Results: Only CTC items regarding hemorrhage GI and GU and incontinence for urine correlated significantly with the corresponding questions of the RPQ and the RCQ. The inter observer agreement was high ($\kappa > 0.5$) for the same items. Only the IPSS item regarding nocturia showed a significant correlation with the matching CTC item. Remaining matching items showed low correlations. The IPSS and corresponding questions from the RCQ had high CCs. The raw agreement was >0.5 except for CTC Ejaculatory dysfunction, where it was 0.41.
Conclusion: Grading with CTC does not allow for accurate scoring of side effects. To overcome this problem self reported questionnaires can be used. Clear guidelines should be made on how to convert data to a CTC grade, to limit inter-observer variability. Questionnaires should be incorporated into daily practice to gather more information on treatment related side-effects.

7043 POSTER

Prediction of biochemical recurrence after radiotherapy treatment for prostate cancer: does PSA response during treatment matter?

R. Houben[1], F. Gils van[2], D. Eekers[3], J. Ten Kate[4], P. Lambin[2].
[1]*Maastricht Radiation Oncology (MAASTRO) Clinic GROW Research Institute Maastricht University, DCM, Maastricht, The Netherlands;*
[2]*Maastricht Radiation Oncology (MAASTRO) Clinic GROW Research Institute Maastricht University, Radiotherapy, Maastricht, The Netherlands;*
[3]*Dr. Bernard Verbeeten Institute, Radiotherapy, Tilburg, The Netherlands;*
[4]*Orbis Medical Park, Clinical Laboratory, Sittard, The Netherlands*

Background: The incidence of prostate cancer is rising in the Western world. Monitoring of total PSA levels, possibly combined with free/total PSA (f/t) ratio, yields valuable information for diagnosis and recurrence after treatment. The goal of the current study was to estimate whether changes in PSA levels during radiotherapy treatment are predictive of the probability of biochemical recurrence during follow up.
Materials and Methods: PSA levels were determined weekly during and at least every three months after radiotherapy treatment for 91 prostate cancer patients (mean age 71.7; sd 5.9 years). All patients were treated with EBRT to a total dose of 68 Gy. Median follow up after treatment was 55 months (range 9−93). Biochemical recurrence was defined as at least two measurements of total PSA level of nadir plus 2 ng/ml or as a start of hormonal treatment. Of all patients, 35 experienced a biochemical failure. Possible predictors of recurrence during radiotherapy treatment were (for both total PSA and f/t ratio) minimum levels, maximum levels, maximum decrease from baseline, maximum increase from baseline and average difference from baseline. The predictors were first studied in univariate logistic regression analyses. Significant predictors were then corrected for age and tumor T stage (N and M stage was 0 in all patients) in multivariate logistic regression analyses after which predictive value of the model was assessed using area under the ROC curve (AUC).
Results: Both minimum total PSA level and maximum f/t ratio were significant predictors from the univariate logistic regression analyses (p respectively 0.04 and 0.025). Both remained significant when corrected for age and T stage. AUC for both models was 0.69 and 0.64 respectively (p respectively 0.003 and 0.024).
Conclusions: Measurement of total PSA levels and f/t ratio during radiotherapy treatment can be predictive of biochemical recurrence afterwards. This applies specifically to the minimum total PSA level and to the maximum f/t ratio. The latter is not surprising since the f/t ratio increases if total PSA levels decrease. There is still room for improvement of the prediction of biochemical recurrence, which should be the subject of a more extensive clinical study incorporating clinical data, blood values apart from PSA and imaging data.

7044 POSTER

Pharmacokinetic analysis of two dosing schedules of the angiokinase inhibitor BIBF 1120 in patients with hormone-refractory prostate cancer who progressed after docetaxel treatment

P. Stopfer[1], J.P. Droz[2], A. Fléchon[2], F. Joly[3], H. de Mont-Serrat[4], R. Kaiser[5], S. Oudard[6]. [1]*Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Drug Metabolism and Pharmacokinetics, Biberach, Germany;* [2]*Centre Léon Bérard, Lyon University, Lyon, France;* [3]*Centre Régional François Baclesse, Department of Oncology, Caen, France;* [4]*Boehringer Ingelheim, Clinical Research, Reims, France;* [5]*Boehringer Ingelheim Pharma GmbH & Co. KG, Clinical Research/Oncology, Biberach, Germany;* [6]*Hôpital Européen Georges Pompidou, Division of Oncology, Paris, France*

Background: BIBF 1120 (Vargatef™*) is a novel, oral, potent angiokinase inhibitor blocking the vascular endothelial growth factor receptor 1/2/3, fibroblast growth factor receptor 1/3, and platelet-derived growth factor receptor α/β tyrosine kinases at nanomolar concentrations. This randomized, open-label, multicenter Phase II study evaluated the efficacy, safety and pharmacokinetics (PK) of two doses of BIBF 1120 in patients with metastatic hormone refractory prostate cancer (HRPC) that had progressed after docetaxel therapy.
Methods: Patients were randomly assigned and treated with BIBF 1120 until disease progression or dose-limiting toxicity. The primary endpoint was response rate defined as a confirmed decline of prostate-specific antigen by $\geqslant$20%. PK analysis was performed for PK samples of 36 patients. PK sampling occurred on Days 1 and 29, and every 2 weeks thereafter. Trough plasma concentrations were taken 8−14 hours after dosing. The distribution of BIBF 1120 plasma concentrations was described using graphs and descriptive statistics.
Results: 81 patients were randomly assigned to receive either 250 mg bid (n = 41) or 150 mg bid (n = 40) of BIBF 1120 as monotherapy. On Day 1, BIBF 1120 plasma con-cen-trations increased within the first 3 hours after dosing in the 150 mg bid and 250 mg bid groups; maximum values were 66.3 ng/mL and 124 ng/mL, respectively. On Day 29, maximum plasma concentrations were 54.9 ng/mL and 112 ng/mL in the 150 mg bid and 250 mg bid groups, respectively. BIBF 1120 plasma levels had reached steady state by Day 29 in both groups; this may have occurred earlier but there was no PK sampling between Days 1 and 29. Overall, pre-dose plasma concentrations remained stable over the 155-day observation period in both groups; interpatient variability was moderate to high. No systematic change in trough plasma concentrations or deviation from dose propor-tio-nality of BIBF 1120 was observed in either group. The gMean pre-dose plasma con-centrations of BIBF 1120 were higher in the 250 mg bid group compared with the 150 mg bid group.
Conclusions: For both dose groups, BIBF 1120 pre-dose concentrations did not deviate from dose-linearity in this study. For both dose groups, pre-dose concentrations remained stable over the treatment period.
*Trade name not FDA approved